{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:32:17Z","timestamp":1792805537810,"version":"4.5.0"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":300,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002660","name":"Islamic Azad University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002660","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.ctarc.2025.101028","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:01:59Z","timestamp":1761696119000},"page":"101028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["PI3K inhibitors: Efficacy in diverse cancer forms"],"prefix":"10.1016","volume":"45","author":[{"given":"Ehsan","family":"kianfar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa M.","family":"Alrudainy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayoob Radhi","family":"Al-Zaalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesam R.","family":"Kadhum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar Yasser","family":"Jassim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2025.101028_bib0001","doi-asserted-by":"crossref","first-page":"7198","DOI":"10.3390\/ijms21197198","article-title":"Inositol polyphosphate-based compounds as inhibitors of phosphoinositide 3-kinase-dependent signaling","volume":"21","author":"Maffucci","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2025.101028_bib0002","first-page":"1","article-title":"The regulation and function of class III PI3Ks: novel roles for Vps34","volume":"10","author":"Backer","year":"2008","journal-title":"Biochem. J."},{"key":"10.1016\/j.ctarc.2025.101028_bib0003","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/138920207782446160","article-title":"The phosphoinositide 3-kinase pathway in Human cancer: genetic alterations and therapeutic implications","volume":"8","author":"Arcaro","year":"2007","journal-title":"Curr. Genom."},{"key":"10.1016\/j.ctarc.2025.101028_bib0004","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signaling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ctarc.2025.101028_bib0005","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri1056","article-title":"PI3K in lymphocyte development, differentiation, and activation","volume":"3","author":"Okkenhaug","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ctarc.2025.101028_bib0006","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.bbamcr.2011.03.010","article-title":"FoxO and regulation of apoptosis","volume":"1813","author":"Zhang","year":"2011","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.ctarc.2025.101028_bib0007","first-page":"2419","article-title":"Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase","volume":"54","author":"Powis","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101028_bib0008","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1016\/S0021-9258(17)37680-9","article-title":"A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)","volume":"269","author":"Vlahos","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ctarc.2025.101028_bib0009","first-page":"LB","article-title":"GDC-0941, a potent, selective, orally bioavailable inhibitor of class I PI3K","volume":"68","author":"Friedman","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101028_bib0010","doi-asserted-by":"crossref","first-page":"802","DOI":"10.18632\/oncotarget.2742","article-title":"The PI3K inhibitor GDC-0941 displays promising In vitro and In vivo efficacy for targeted medulloblastoma therapy","volume":"6","author":"Ehrhardt","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctarc.2025.101028_bib0011","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ctarc.2025.101028_bib0012","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ctarc.2025.101028_bib0013","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev.biochem.67.1.481","article-title":"P.hosphoinositide kinases","volume":"67","author":"Fruman","year":"1998","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ctarc.2025.101028_bib0014","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","article-title":"The PI3K pathway as drug target in Human cancer","volume":"28","author":"Courtney","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.101028_bib0015","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1126\/science.1096502","article-title":"Frequency of mutations of the PIK3CA gene in Human cancers","volume":"304","author":"Samuels","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ctarc.2025.101028_bib0016","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.4161\/cc.3.10.1164","article-title":"Oncogenic mutations of PIK3CA in Human cancers","volume":"3","author":"Samuels","year":"2004","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ctarc.2025.101028_bib0017","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ccr.2005.08.008","article-title":"The Akt-MTOR tango and its relevance to cancer","volume":"8","author":"Hay","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctarc.2025.101028_bib0018","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","article-title":"The PI3K pathway as drug target in Human cancer","volume":"28","author":"Courtney","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.101028_bib0019","first-page":"546","article-title":"PI3K pathway as a potential target for therapy of hormone refractory prostate cancer","volume":"21","author":"Yaguchi","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2025.101028_bib0020","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-kinase AKT pathway in Human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ctarc.2025.101028_bib0021","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nrd1902","article-title":"Exploiting the PI3K\/AKT pathway for cancer drug discovery","volume":"4","author":"Hennessy","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ctarc.2025.101028_bib0022","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism","volume":"7","author":"Engelman","year":"2006","journal-title":"Nat. Rev. Genet"},{"key":"10.1016\/j.ctarc.2025.101028_bib0023","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1210\/en.2002-0157","article-title":"Androgen stimulates matrix metalloproteinase-2 expression in Human prostate cancer","volume":"144","author":"Liao","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctarc.2025.101028_bib0024","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.ctarc.2025.101028_bib0025","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nature05933","article-title":"A transforming mutation in the Pleckstrin homology domain of AKT1 in cancer","volume":"448","author":"Carpten","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2025.101028_bib0026","doi-asserted-by":"crossref","first-page":"7482","DOI":"10.1038\/sj.onc.1209088","article-title":"The AKT\/PKB pathway: molecular target for cancer drug discovery","volume":"24","author":"Cheng","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ctarc.2025.101028_bib0027","first-page":"938","article-title":"Androgen receptor gene mutation in prostate cancer and stromal cells","volume":"94","author":"Li","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ctarc.2025.101028_bib0028","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1038\/onc.2008.245","article-title":"PI3K pathway alterations in cancer: variations on a theme","volume":"27","author":"Yuan","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ctarc.2025.101028_bib0029","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1038\/onc.2008.246","article-title":"Drug discovery approaches targeting the PI3K-AKT pathway in cancer","volume":"27","author":"Garcia-Echeverria","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ctarc.2025.101028_bib0030","doi-asserted-by":"crossref","first-page":"31372","DOI":"10.1074\/jbc.271.49.31372","article-title":"Expression of a constitutively active akt ser\/thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation","volume":"271","author":"Kohn","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ctarc.2025.101028_bib0031","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1535-6108(03)00248-4","article-title":"Targeting the PI3K-AKT pathway in Human cancer: rationale and promise","volume":"4","author":"Luo","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctarc.2025.101028_bib0032","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.ctarc.2025.101028_bib0033","first-page":"75","article-title":"Akt directly regulates 14-3-3\u03b6 expression to control the response to mechanical stimulation in Human caco-2 intestinal epithelial cells","volume":"379","author":"Wang","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ctarc.2025.101028_bib0034","doi-asserted-by":"crossref","first-page":"10455","DOI":"10.1158\/0008-5472.CAN-07-2057","article-title":"Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity","volume":"67","author":"Zoubeidi","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101028_bib0035","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1158\/0008-5472.CAN-08-3472","article-title":"eIF4E Activation is commonly elevated in advanced Human prostate cancers and significantly related to reduced patient survival","volume":"69","author":"Graff","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101028_bib0036","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cellsig.2009.01.004","article-title":"Akt-dependent and -independent mechanisms of mTOR regulation in cancer","volume":"21","author":"Memmott","year":"2009","journal-title":"Cell. Signal"},{"key":"10.1016\/j.ctarc.2025.101028_bib0037","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0092-8674(00)00117-3","article-title":"TOR, a Central controller of cell growth","volume":"103","author":"Schmelzle","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ctarc.2025.101028_bib0038","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ceb.2009.01.024","article-title":"mTOR and the control of whole body metabolism","volume":"21","author":"Polak","year":"2009","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.ctarc.2025.101028_bib0039","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1242\/jcs.051011","article-title":"mTOR signaling at a glance","volume":"122","author":"Laplante","year":"2009","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ctarc.2025.101028_bib0040","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1126\/science.1715094","article-title":"Targets for cell cycle arrest by the immunosuppressant rapamycin in Yeast","volume":"253","author":"Heitman","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.ctarc.2025.101028_bib0041","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0092-8674(94)90570-3","article-title":"RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs","volume":"78","author":"Sabatini","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.ctarc.2025.101028_bib0042","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/369756a0","article-title":"A mammalian protein targeted by G1-arresting rapamycin\u2013Receptor complex","volume":"369","author":"Brown","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2025.101028_bib0043","first-page":"413","article-title":"Physiological coupling of receptor and hormone action","volume":"48","author":"Lynch","year":"1996","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ctarc.2025.101028_bib0044","first-page":"167","article-title":"Resistance to second-generation antiandrogen therapy in prostate cancer: an emerging role for mTOR pathway targeting","volume":"20","author":"Klotz","year":"2017","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.ctarc.2025.101028_bib0045","first-page":"5092","article-title":"Synergistic anticancer activity of a glycogen synthase kinase-3 inhibitor and rapamycin in prostate cancer cells","volume":"13","author":"Xu","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101028_bib0046","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ctarc.2025.101028_bib0047","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1200\/JCO.2011.39.7356","article-title":"Management of metabolic effects associated with anticancer agents targeting the PI3K-akt-mTOR pathway","volume":"30","author":"Busaidy","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.101028_bib0048","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1200\/JCO.2011.39.7356","article-title":"Management of metabolic effects associated with anticancer agents targeting the PI3K-akt-mTOR pathway","volume":"30","author":"Busaidy","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.101028_bib0049","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev.pharmtox.47.120505.105304","article-title":"AMP-activated protein kinase as a drug target","volume":"47","author":"Hardie","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ctarc.2025.101028_bib0050","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1182\/blood-2010-02-269837","article-title":"The LKB1\/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2025.101028_bib0051","first-page":"18541","article-title":"Osmotic shock inhibits insulin signaling by dephosphorylating protein kinase B (PKB\/Akt) at Ser473 and Thr308","volume":"274","author":"Chen","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ctarc.2025.101028_bib0052","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.tibs.2003.11.007","article-title":"TSC2: filling the GAP in the mTOR signaling pathway","volume":"29","author":"Li","year":"2004","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ctarc.2025.101028_bib0053","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S1097-2765(03)00220-X","article-title":"Insulin activation of Rheb, a mediator of mTOR\/S6K\/4E-BP signaling, is inhibited by TSC1 and 2","volume":"11","author":"Garami","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ctarc.2025.101028_bib0054","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","article-title":"From growth signal integration to cancer, diabetes and ageing","volume":"12","author":"Zoncu","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101028_bib0055","first-page":"257","article-title":"Exploring the versatile pharmacological potential of indole derivatives: a comprehensive review","volume":"8","author":"Mubassir","year":"2025","journal-title":"Prog. Chem. Biochem. Res."},{"issue":"2","key":"10.1016\/j.ctarc.2025.101028_bib0056","first-page":"171","article-title":"Analgesic, anti-inflammatory, and anti-brain tumor activities of melastomastrum capitatum A. and R. Fern. Leaf methanol extract in wistar rats","volume":"8","author":"Ukwubile","year":"2025","journal-title":"Prog. Chem. Biochem. Res."},{"issue":"2","key":"10.1016\/j.ctarc.2025.101028_bib0057","first-page":"191","article-title":"Recent progress in biomaterial \u2013 enhanced transarterial embolization for primary liver cancer therapy: a short review'","volume":"8","author":"Mahmoodiyan","year":"2025","journal-title":"Prog. Chem. Biochem. Res."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101028_bib0058","first-page":"182","article-title":"Preliminary anticancer activity, antimicrobial activity, and brine shrimp lethality bioassay fractions of ficus platyphylla del. Stem bark","volume":"6","author":"Sadiq","year":"2024","journal-title":"Adv. J. Chem. B: Nat. Prod. Med. Chem."},{"issue":"10","key":"10.1016\/j.ctarc.2025.101028_bib0059","first-page":"851","article-title":"Design, synthesis and evaluation of novel phenyl-(1-morpholine-4-dimethyl\/piperazin-1-ylmethyl)-1H-indol-3-ylmethylene amine derivatives against breast cancer cells","volume":"9","author":"Gadhave","year":"2025","journal-title":"Chem. Methodol."},{"issue":"10","key":"10.1016\/j.ctarc.2025.101028_bib0060","first-page":"938","article-title":"A systematic review on the role of silver nanoparticles in treatment of oral cancer","volume":"9","author":"Safaei","year":"2025","journal-title":"Chem. Methodol."},{"issue":"9","key":"10.1016\/j.ctarc.2025.101028_bib0061","first-page":"771","article-title":"Synthesis, characterization, and adsorption studies of functionalized graphene oxide via covalent interactions","volume":"9","author":"Nouri Mollalar","year":"2025","journal-title":"Chem. Methodol."},{"issue":"4","key":"10.1016\/j.ctarc.2025.101028_bib0062","first-page":"366","article-title":"Comprehensive review of Schiff base sulphonamides: synthesis, biological activity, and marketed applications","volume":"5","author":"Mubassir","year":"2025","journal-title":"Eurasian J. Sci. Technol."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101028_bib0063","first-page":"304","article-title":"Synthesis, characterization of silver nanoparticles of Ziziphus plant extracts and investigation of their biological activities: antibacterial and anticancer","volume":"5","author":"Adress. Hassan","year":"2025","journal-title":"J. Appl. Organomet. Chem."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101028_bib0064","first-page":"343","article-title":"Extraction, phytochemical screening, green synthesis of silver nanoparticles (Ag-NPs), and antioxidant potential of Aphanamixis polystachya","volume":"5","author":"Balaji","year":"2025","journal-title":"J. Appl. Organomet. Chem."},{"issue":"2","key":"10.1016\/j.ctarc.2025.101028_bib0065","first-page":"97","article-title":"Synthesis of tetrahydrobenzo[b]pyran derivatives using reusable CoFe\u2082O\u2084@SiO\u2082-CPTES-melamine-Cu nanocatalyst","volume":"5","author":"Ali","year":"2025","journal-title":"J. Appl. Organomet. Chem."},{"issue":"2","key":"10.1016\/j.ctarc.2025.101028_bib0066","first-page":"60","article-title":"Exploring the diverse ethnopharmacological applications of Urtica dioica L.: an extensive review","volume":"6","author":"Dhaka","year":"2024","journal-title":"J. Agric. Sci. Eng."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101028_bib0067","first-page":"267","article-title":"Schiff base indole derivatives: synthesis and biological activities- a comprehensive review","volume":"7","author":"Mubassir","year":"2025","journal-title":"J. Med. Nanomater. Chem."},{"issue":"2","key":"10.1016\/j.ctarc.2025.101028_bib0068","first-page":"130","article-title":"Biogenic synthesis of hexagonal silver nanoparticles in Cannonball flower extract exhibits antibacterial, antioxidant and anticancer effective trio bioactivities","volume":"7","author":"Sawant","year":"2025","journal-title":"J. Med. Nanomater. Chem."},{"issue":"2","key":"10.1016\/j.ctarc.2025.101028_bib0069","first-page":"148","article-title":"Synthesis, characterization and pharmacological evaluation some newly Schiff base sulphonamide derivative","volume":"7","author":"Ahmad","year":"2025","journal-title":"J. Med. Nanomater. Chem."},{"issue":"2","key":"10.1016\/j.ctarc.2025.101028_bib0070","first-page":"116","article-title":"Molecular docking and Network pharmacology: investigating Vitis vinifera phytoconstituents as multi-target therapeutic agents against breast cancer","volume":"1","author":"Shaikh","year":"2025","journal-title":"J. Pharm. Sci. Comput. Chem."},{"key":"10.1016\/j.ctarc.2025.101028_bib0071","unstructured":"National Center for Biotechnology Information (2025). PubChem compound summary for CID 24197366. Retrieved August 27, 2025 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/24197366."},{"key":"10.1016\/j.ctarc.2025.101028_bib0072","unstructured":"National Center for Biotechnology Information (2025). PubChem compound summary for CID 664662, 6-methoxy-3-(5-phenyl-1,2,4-oxadiazol-3-yl)quinolin-2(1H)-one. Retrieved August 27, 2025 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/664662."},{"key":"10.1016\/j.ctarc.2025.101028_bib0073","unstructured":"National Center for Biotechnology Information (2025). PubChem compound summary for CID 68917150, 2-(2-methyl-1H-imidazol-1-yl)-1H-benzo[d]imidazole. Retrieved August 27, 2025 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/2-_2-methyl-1H-imidazol-1-yl_-1H-benzo_d_imidazole."},{"key":"10.1016\/j.ctarc.2025.101028_bib0074","unstructured":"National Center for Biotechnology Information (2025). PubChem compound summary for CID 122184946. Retrieved August 27, 2025 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/122184946."},{"key":"10.1016\/j.ctarc.2025.101028_bib0075","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ejmech.2018.03.076","article-title":"An overview of quinazolines: pharmacological significance and recent developments","volume":"151","author":"Alagarsamy","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ctarc.2025.101028_bib0076","unstructured":"National Center for Biotechnology Information (2025). PubChem compound summary for CID 155549676, 5-[4-[2-(Dimethylamino)ethylamino]quinazolin-6-yl]-2-methoxypyridine-3-carbonitrile. Retrieved August 28, 2025 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/155549676."},{"key":"10.1016\/j.ctarc.2025.101028_bib0077","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ejmech.2018.08.017","article-title":"Recent advancement of piperidine moiety in treatment of cancer-A review","volume":"157","author":"Goel","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ctarc.2025.101028_bib0078","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/open.202100141","article-title":"Synthesis and antiprotozoal profile of 3, 4, 5-trisubstituted isoxazoles","volume":"10","author":"Rosa","year":"2021","journal-title":"ChemistryOpen"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101028_bib0079","article-title":"Anticancer, anti-inflammatory, and analgesic activities of synthesized 2-(substituted phenoxy) acetamide derivatives","volume":"2014","author":"Rani","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ctarc.2025.101028_bib0080","unstructured":"National Center for Biotechnology Information (2025). PubChem compound summary for CID 59564705. Retrieved August 28, 2025 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/59564705."},{"issue":"21","key":"10.1016\/j.ctarc.2025.101028_bib0081","doi-asserted-by":"crossref","first-page":"9302","DOI":"10.1039\/D1NJ00704A","article-title":"Functionalization of imidazo [1, 2-a] pyridines via radical reactions","volume":"45","author":"Ma","year":"2021","journal-title":"New J. Chem."},{"issue":"7","key":"10.1016\/j.ctarc.2025.101028_bib0082","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2174\/1389557511313070003","article-title":"Hydrazides\/hydrazones as antimicrobial and anticancer agents in the new millennium","volume":"13","author":"Kumar","year":"2013","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ctarc.2025.101028_bib0083","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ejmech.2017.01.016","article-title":"Discovery of a series of N-(5-(quinolin-6-yl) pyridin-3-yl) benzenesulfonamides as PI3K\/mTOR dual inhibitors","volume":"127","author":"Zhang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ctarc.2025.101028_bib0084","unstructured":"National Center for Biotechnology Information (2025). PubChem compound summary for CID 162663726. Retrieved August 28, 2025 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/162663726."},{"key":"10.1016\/j.ctarc.2025.101028_bib0085","unstructured":"National Center for Biotechnology Information (2025). PubChem compound summary for CID 58258904, (5-Fluoro-6-methoxypyridin-3-YL)methanamine. Retrieved August 28, 2025 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/5-Fluoro-6-methoxypyridin-3-YL_methanamine."},{"key":"10.1016\/j.ctarc.2025.101028_bib0086","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ejmech.2017.01.016","article-title":"Discovery of a series of N-(5-(quinolin-6-yl) pyridin-3-yl) benzenesulfonamides as PI3K\/mTOR dual inhibitors","volume":"127","author":"Zhang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ctarc.2025.101028_bib0087","article-title":"Patent application title: compounds and methods for treating pain inventors: Josef Penninger (Vienna, AT) Josef Penninger (Vienna, AT) Graham Gregory Neely (Sydney, AU) Shane Mcmanus (Vienna, AT) Henrik Nilsson (Vienna, AT)","author":"Class","year":"2013","journal-title":"J. Pharmacol. Exp. Ther"},{"issue":"3","key":"10.1016\/j.ctarc.2025.101028_bib0088","first-page":"493","article-title":"Crystal structure of methyl 2-acetamido-5-chlorbenzoate, C10H10ClNO3","volume":"232","author":"Zhao","year":"2017","journal-title":"Z. Krist.-New Cryst. Struct."},{"key":"10.1016\/j.ctarc.2025.101028_bib0089","unstructured":"National Center for Biotechnology Information (2025). PubChem compound summary for CID 59564705. Retrieved August 28, 2025 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/59564705."},{"issue":"20","key":"10.1016\/j.ctarc.2025.101028_bib0090","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1016\/j.bmc.2017.08.022","article-title":"Synthesis and biological evaluation of 8-aryl-2-morpholino-7-O-substituted benzo [e][1, 3] oxazin-4-ones against DNA-PK, PI3K, PDE3A enzymes and platelet aggregation","volume":"25","author":"Saifuzzaman","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ctarc.2025.101028_bib0091","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ejmech.2016.01.042","article-title":"Synthesis, structure elucidation, DNA-PK and PI3K and anti-cancer activity of 8-and 6-aryl-substituted-1-3-benzoxazines","volume":"110","author":"Morrison","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ctarc.2025.101028_bib0092","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116832","article-title":"Synthesis and biological evaluation of 4H-benzo [e][1, 3] oxazin-4-ones analogues of TGX-221 as inhibitors of PI3K\u03b2","volume":"69","author":"Mohammed","year":"2022","journal-title":"Bioorg. Med. Chem."},{"issue":"23","key":"10.1016\/j.ctarc.2025.101028_bib0093","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.1016\/j.bmcl.2010.10.021","article-title":"Identification and structure\u2013activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors","volume":"20","author":"Pecchi","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101028_bib0094","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1021\/jp310470f","article-title":"Origin of the conformational modulation of the 13C NMR chemical shift of methoxy groups in aromatic natural compounds","volume":"117","author":"Tou\u0161ek","year":"2013","journal-title":"J. Phys. Chem. A"},{"key":"10.1016\/j.ctarc.2025.101028_bib0095","unstructured":"National Center for Biotechnology Information (2025). PubChem compound summary for CID 56718352, 2-{[6-(1H-Indol-4-YL)quinazolin-4-YL]amino}ethanol. Retrieved August 28, 2025 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/56718352."},{"issue":"19","key":"10.1016\/j.ctarc.2025.101028_bib0096","doi-asserted-by":"crossref","first-page":"4571","DOI":"10.1016\/j.bmcl.2017.08.053","article-title":"Design, synthesis, and SAR study of 3-(benzo [d][1, 3] dioxol-5-yl)-N-benzylpropanamide as novel potent synergists against fluconazole-resistant Candida albicans","volume":"27","author":"Cai","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ctarc.2025.101028_bib0097","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.875372","article-title":"Recent advances in dual PI3K\/mTOR inhibitors for tumour treatment","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ctarc.2025.101028_bib0098","unstructured":"National Center for Biotechnology Information (2025). PubChem compound summary for CID 71509211, 6-bromo-8-ethoxy-3-nitro-2H-chromene. Retrieved August 28, 2025 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/6-bromo-8-ethoxy-3-nitro-2H-chromene."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101028_bib0099","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s12672-025-02471-w","article-title":"Modulation of the PI3K\/Akt signaling pathway by resveratrol in cancer: molecular mechanisms and therapeutic opportunity","volume":"16","author":"Hedayati","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.ctarc.2025.101028_bib0100","article-title":"Quercetin promises anticancer activity through PI3K-AKT-mTOR pathway: a literature review","author":"Hasan","year":"2025","journal-title":"Pharmacol. Res.-Nat. Prod."},{"issue":"8","key":"10.1016\/j.ctarc.2025.101028_bib0101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-025-02844-9","article-title":"Coumarin derivatives as anticancer agents targeting PI3K-AKT-mTOR pathway: a comprehensive literature review","volume":"42","author":"Al Hasan","year":"2025","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ctarc.2025.101028_bib0102","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116850","article-title":"Strategic advancements in targeting the PI3K\/AKT\/mTOR pathway for breast cancer therapy","author":"Garg","year":"2025","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.ctarc.2025.101028_bib0103","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3390\/ijms26051868","article-title":"A comprehensive review of nanoparticle-based drug delivery for modulating PI3K\/AKT\/mTOR-mediated autophagy in cancer","volume":"26","author":"Rahman","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101028_bib0104","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12935-025-03658-5","article-title":"Molecular pathways in reproductive cancers: a focus on prostate and ovarian cancer","volume":"25","author":"Ajayi","year":"2025","journal-title":"Cancer Cell Int."},{"issue":"14","key":"10.1016\/j.ctarc.2025.101028_bib0105","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.3390\/ijms26146853","article-title":"The role of PI3K\/AKT\/mTOR signaling in tumor radioresistance and advances in inhibitor research","volume":"26","author":"Zhan","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101028_bib0106","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3390\/vaccines13030292","article-title":"Targeting PI3K signaling to overcome tumor immunosuppression: synergistic strategies to enhance cancer vaccine efficacy","volume":"13","author":"Cui","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ctarc.2025.101028_bib0107","doi-asserted-by":"crossref","first-page":"x12","DOI":"10.1093\/annonc\/mdz381","article-title":"Efficacy of PI3K inhibitors in advanced breast cancer","volume":"30","author":"Verret","year":"2019","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2025.101028_bib0108","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s43018-021-00218-4","article-title":"The present and future of PI3K inhibitors for cancer therapy","volume":"2","author":"Castel","year":"2021","journal-title":"Nat. Cancer"},{"issue":"10","key":"10.1016\/j.ctarc.2025.101028_bib0109","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/aps.2015.71","article-title":"PI3K isoform-selective inhibitors: next-generation targeted cancer therapies","volume":"36","author":"Wang","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"issue":"6","key":"10.1016\/j.ctarc.2025.101028_bib0110","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00280-013-2121-1","article-title":"PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types","volume":"71","author":"Britten","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"23","key":"10.1016\/j.ctarc.2025.101028_bib0111","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1039\/D0SC01676D","article-title":"PI3K inhibitors: review and new strategies","volume":"11","author":"Zhang","year":"2020","journal-title":"Chem. Sci."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101028_bib0112","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3390\/cancers15030703","article-title":"Current state and future challenges for PI3K inhibitors in cancer therapy","volume":"15","author":"Sirico","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ctarc.2025.101028_bib0113","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ctarc.2025.101028_bib0114","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/OTT.S89967","article-title":"PI3K inhibitors as new cancer therapeutics: implications for clinical trial design","author":"Massacesi","year":"2016","journal-title":"Onco. Targets Ther."},{"issue":"11","key":"10.1016\/j.ctarc.2025.101028_bib0115","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2025.101028_bib0116","first-page":"157","article-title":"Zydelig (Idelalisib): first-in-class PI3 kinase inhibitor approved for the treatment of 3 hematologic malignancies","volume":"8","author":"Raedler","year":"2015","journal-title":"Am. Health Drug Benefits"},{"issue":"35","key":"10.1016\/j.ctarc.2025.101028_bib0117","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.ctarc.2025.101028_bib0118","first-page":"2446","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL. Blood","volume":"132","author":"Flinn","year":"2018","journal-title":"J. Am. Soc. Hematol."},{"issue":"13","key":"10.1016\/j.ctarc.2025.101028_bib0119","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.2017.72.7107","article-title":"Phosphatidylinositol 3-kinase \u03b1\u2013selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study","volume":"36","author":"Juric","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2025.101028_bib0120","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.4475","article-title":"Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor\u2013positive advanced breast cancer: a phase 1b clinical trial","volume":"5","author":"Juric","year":"2019","journal-title":"JAMA Oncol."},{"issue":"20","key":"10.1016\/j.ctarc.2025.101028_bib0121","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor\u2013positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.ctarc.2025.101028_bib0122","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a dual PI3K\u03b4\/CK1\u03b5 inhibitor in patients with relapsed or refractory indolent lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101028_bib0123","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ctarc.2025.101028_bib0124","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2024.111073","article-title":"A comprehensive review on phosphatidylinositol-3-kinase (PI3K) and its inhibitors bearing pyrazole or indazole core for cancer therapy","volume":"398","author":"Bastos","year":"2024","journal-title":"Chem. Biol. Interact."},{"issue":"5","key":"10.1016\/j.ctarc.2025.101028_bib0125","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.ctarc.2025.101028_bib0126","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1158\/1078-0432.CCR-10-0540","article-title":"A unique spectrum of somatic PIK3CA (p110\u03b1) mutations within primary endometrial carcinomas","volume":"17","author":"Rudd","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.ctarc.2025.101028_bib0127","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ccell.2014.08.017","article-title":"Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors","volume":"26","author":"Cheung","year":"2014","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.ctarc.2025.101028_bib0128","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrclinonc.2013.10","article-title":"Development of PI3K inhibitors: lessons learned from early clinical trials","volume":"10","author":"Rodon","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225001649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225001649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:38:37Z","timestamp":1765485517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225001649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":128,"alternative-id":["S2468294225001649"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.101028","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PI3K inhibitors: Efficacy in diverse cancer forms","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.101028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101028"}}